USP17L16P

Across TCGA pan-cancer cohorts, USP17L16P RNA is linked to patient survival in 6 of 34 cancer types, making it the most broadly survival-associated USP17L16P data layer.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher USP17L16P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated USP17L16P expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LUSC, SKCM, and LAML are the cancer types where USP17L16P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Tertile	All	0.178	0.760	<.001	36	view →
SKCM	OS	Tertile	All	0.215	0.781	<.001	18	view →
LAML	DFS	Tertile	All	0.111	0.571	.018	18	view →
MESO	DFS	Tertile	All	0.098	0.366	.039	18	view →
BRCA	DFS	Tertile	All	0.131	0.527	.004	12	view →
GBM	OS	Tertile	All	1.000	0.257	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

USP17L16P–LUSC (DFS)

Open the LUSC breakdown →